TICKERNERD
Menu
PENPENHealthcare · Medical Devices

PEN Stock Forecast: Penumbra, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$327
+0.08% on the day

The 16 Wall Street analysts covering Penumbra, Inc. hold a median 12-month price target of $374 — +14.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 75 of 100 as at 15 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$12.9B
Ticker Nerd rank
75 / 100
Median analyst target
$374
Analysts covering
16
Total return, dividends reinvested
1W
+0.7%
1M
+3.4%
YTD
+5.2%
1Y
+29.1%
From 52W high
−9.0%
From 52W low
+45.0%
$226
$359
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PEN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Penumbra, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
75 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
100
Quality
94
Momentum
83
Issuance
68
Value
66
Growth
56
Accruals
55
Revisions
44
Size
14

Volatility (100): The share price has been relatively steady.

Revisions (44): Analysts have, on balance, been cutting their forecasts.

Size (14): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PEN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PEN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$200$250$300$350$400Oct 25Jan 26Apr 26Jul 26PENHigh $374Median $374Low $323

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says16 analysts
3 Buy13 Hold0 Sell
Low $323Median $374High $374

The green dot is the last close — the median target sits +14.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
6 July 2026Evercore ISI GroupMaintainsOutperform$335 → $320
11 June 2026RBC CapitalReiteratesSector Perform—
7 May 2026CitigroupMaintainsNeutral—
7 May 2026Evercore ISI GroupMaintainsOutperform—
26 Feb 2026Evercore ISI GroupMaintainsOutperform—
20 Jan 2026Canaccord GenuityDowngradeHold—
20 Jan 2026RBC CapitalDowngradeSector Perform—
16 Jan 2026BairdDowngradeNeutral—
16 Jan 2026BTIGDowngradeNeutral—
16 Jan 2026CitigroupDowngradeNeutral—
16 Jan 2026JefferiesDowngradeHold—
16 Jan 2026Leerink PartnersDowngradeMarket Perform—
16 Jan 2026NeedhamDowngradeHold—
16 Jan 2026Truist SecuritiesDowngradeHold—
15 Jan 2026Wells FargoDowngradeEqual-Weight—
15 Jan 2026William BlairDowngradeMarket Perform—
5 Jan 2026B of A SecuritiesMaintainsBuy—
18 Dec 2025JP MorganUpgradeOverweight—
18 Dec 2025Truist SecuritiesMaintainsBuy—
17 Dec 2025Canaccord GenuityMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PEN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

PEN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−6.0%
Analysts raising
0
Analysts cutting
2
Fundamentals

Penumbra, Inc. (PEN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
80.5×

Cheaper than 9% of US stocks

Price / sales
8.6×

Cheaper than 16% of US stocks

Price / book
8.4×

Cheaper than 13% of US stocks

EV / EBITDA
60.9×

Cheaper than 4% of US stocks

Growth & margins
Revenue growth (YoY)
14.9%

Higher than 62% of US stocks

Earnings growth (YoY)
−23.1%

Higher than 18% of US stocks

Gross margin
67.9%

Higher than 81% of US stocks

Operating margin
10.5%

Higher than 65% of US stocks

Net margin
10.7%

Higher than 71% of US stocks

Returns & dividend
Return on equity
11.4%

Higher than 67% of US stocks

Return on assets
6.4%

Higher than 83% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

PEN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
PENPenumbra, Inc.$12.9B
75
GMEDGlobus Medical, Inc.$11.6B
96
GKOSGlaukos Corp.$10.9B
90
PODDInsulet Corp.$9.9B
89
BIOBio-Rad Laboratories, Inc.$9.5B
90
BRKRBruker Corp.$8.8B
82
ZBHZimmer Biomet Holdings, Inc.$19.9B
91

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Penumbra, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PEN news & analysis

TFX vs. PEN: Which Stock Is the Better Value Option?

Zacks Investment Research · 10 Aug 2026neutral

Zacks Investment Research published an article comparing Teleflex (TFX) and Penumbra (PEN) as value opportunities for investors in the Medical - Instruments sector. The piece examines which of the two stocks offers the better value option at this time.

Why it matters — Penumbra watchers would care because the article directly assesses PEN as a value investment relative to a sector peer, offering perspective on how the stock is being perceived by analysts.

Penumbra, Inc. Reports Second Quarter 2026 Financial Results

PRNewsWire · 30 July 2026neutral

Penumbra, Inc. announced its financial results for the second quarter ended June 30, 2026, via a press release on July 30, 2026.

Why it matters — The quarterly financial report provides investors with an update on the company's performance and financial health for the most recent quarter.

FAQ

Frequently asked questions about PEN stock

What is the PEN stock price forecast for 2026-2027?

The 16 Wall Street analysts covering Penumbra, Inc. have a median 12-month price target of $374, with estimates ranging from $323 to $374. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PEN stock a buy right now?

Of the 16 analysts covering Penumbra, Inc., 3 rate it a Buy, 13 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Penumbra, Inc. 75 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PEN?

As at 15 Aug 2026, Penumbra, Inc. ranks 75 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (100 of 100).

Will PEN stock go up?

No one can know that. What the data says: the median 12-month target from 16 analysts implies +14.4% from the last close, and Ticker Nerd's factor model ranks Penumbra, Inc. 75 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PEN stock forecast for 2030?

No analyst covering Penumbra, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PEN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $323 to $374 over the next 12 months.

How has PEN stock performed over the past year?

Penumbra, Inc. returned +29.1% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Penumbra, Inc. do?

Penumbra Inc. is a prominent player in the healthcare sector, focusing primarily on the development and commercialization of innovative medical devices.

What is the latest news on PEN?

The most recent item we track (Zacks Investment Research, 10 Aug 2026): "TFX vs. PEN: Which Stock Is the Better Value Option?". Zacks Investment Research published an article comparing Teleflex (TFX) and Penumbra (PEN) as value opportunities for investors in the Medical - Instruments sector. The piece examines which of the two stocks offers the better value option at this time.

Company

About Penumbra, Inc.

Penumbra Inc. is a prominent player in the healthcare sector, focusing primarily on the development and commercialization of innovative medical devices. Known for its customer-centric approach, the company operates within the specialized field of interventional therapies, particularly in neuro and vascular medical devices. Penumbra’s products are crucial for addressing critical conditions such as stroke and peripheral artery diseases. By pioneering minimally invasive solutions, the company significantly contributes to enhancing patient outcomes and reshaping intervention methods in the medical field. Founded in 2004 and headquartered in Alameda, California, Penumbra plays a vital role in the medical device industry with its commitment to advancing healthcare technologies. Its solutions are not only pivotal in specialized medical procedures but also support the healthcare ecosystem's broader objective of improving care and saving lives, making it a key entity amongst healthcare providers and hospitals worldwide.

CEO Mr. Adam Elsesser J.D. · 4,700 employees · United States · https://www.penumbrainc.com